To further assess the effectiveness of immunotherapy in patients with cancer, this study estimated the correlation between the common immune checkpoints PD1, PD-L1, PD-L2, CTLA4, and the risk scores (Fig. 10 E–L). This evidence concerns the gene PDCD1 and cancer.